MEDIROM Healthcare Technologies Inc.(MRM)Earnings, Financials & Key RatiosMEDIROM Healthcare Technologies Inc. (MRM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q2
the company's inability to generate positive free cash flow, combined with a 0.24 current ratio, indicates severe liquidity constraints that threaten long-term solvency.
MEDIROM Healthcare Technologies Inc. (MRM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
MEDIROM Healthcare Technologies Inc. (MRM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.05 | $4Mvs $4M+0.0% |
| Q2 2025 | Apr 29, 2025 | $0.79 | $31M |
| Q3 2024 | Jun 30, 2024 | $0.74 | $22M |
| Q3 2024 | Jun 18, 2024 | $0.62 | $26M |
Recent stock market news and headlines for MEDIROM Healthcare Technologies Inc. (MRM)
Additional Orders Triple Implementation Scale; "MOTHER Bracelet®" Enables Continuous Safety Monitoring During Extended Training Additional Orders Triple Implementation Scale; "MOTHER Bracelet®" Enables Continuous Safety Monitoring During Extended Training
Toronto, Ontario and New York, New York--(Newsfile Corp. - June 23, 2026) - Micromem Technologies Inc. (CSE: MRM) (OTCQB: MMTIF) ("Micromem" or the "Company") is pleased to provide an update following recent meetings with representatives of the Department of National Defence ("DND"). The Company has now completed its initial cost analysis and engineering review of the wearable unit prototype.
Toronto, Ontario and New York, New York--(Newsfile Corp. - June 18, 2026) - Micromem Technologies Inc. (CSE: MRM) (OTCQB: MMTIF) ("Micromem" or the "Company") announces closing of its non-brokered private placement (the "Private Placement") previously announced in its news release issued on June 9, 2026. Micromem raised gross proceeds of approximately C$235,000 by placing a total of 9,400,000 units at a price of C$0.025 per unit, each unit being comprised of one common share and one warrant exercisable at C$0.05 per share for a period of two years following the issuance date.
Key metrics vs top competitors for MEDIROM Healthcare Technologies Inc. (MRM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.00 | $5.09M | 6.02 | 21.55% | 1.79% | 21.19% | — | |
| $7.05 | $263.05M | -4.80 | -1.71% | -11.1% | — | — | |
| $52.74 | $4.19B | 20.13 | 12.06% | 16.52% | — | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $33.94 | $7.45B | 66.55 | 59% | -0.56% | -2.48% | — | |
| $104.50 | $6.92B | 76.28 | 15.24% | 9.48% | 5.13% | — |
MEDIROM Healthcare Technologies Inc. (MRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when MRM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MEDIROM Healthcare Technologies Inc. (MRM) stock FAQ — growth, dividends, profitability & financials explained
MEDIROM Healthcare Technologies Inc. (MRM) reported $15.04B in revenue for fiscal year 2024. This represents a 338% increase from $3.43B in 2018.
MEDIROM Healthcare Technologies Inc. (MRM) grew revenue by 21.5% over the past year. This is strong growth.
MEDIROM Healthcare Technologies Inc. (MRM) reported a net loss of $51.8M for fiscal year 2024.
MEDIROM Healthcare Technologies Inc. (MRM) has a return on equity (ROE) of 21.2%. This is excellent, indicating efficient use of shareholder capital.
MEDIROM Healthcare Technologies Inc. (MRM) had negative free cash flow of $2.36B in fiscal year 2024, likely due to heavy capital investments.
